Astrazeneca Pharmaceuticals Lp
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$309Mgeneral payments (2019-2025)
$219Kresearch payments (2019-2025)
297,302clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Airsupra $26M associated (2023-2025)
- Breztri $19M associated (2023-2025)
- Farxiga $18M associated (2023-2025)
- Tezspire $14M associated (2023-2025)
- Fasenra $12M associated (2023-2025)
- Imfinzi $9.4M associated (2023-2025)
- Saphnelo $6.7M associated (2023-2025)
- Lynparza $6.0M associated (2023-2025)
- Calquence $5.2M associated (2023-2025)
- Enhertu $4.8M associated (2023-2025)
- Tagrisso $4.6M associated (2023-2025)
- Lokelma $3.5M associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Michael Marcus | Brooklyn, NY | Pediatric Allergy/Immunology | $1,069,905.35 |
| Ruth Penn | Ellicott City, MD | $999,700.19 | |
| David Mares | Anderson, IN | Pulmonary Disease | $941,653.63 |
| Robert Gasser | Washington, DC | Infectious Disease | $922,180.80 |
| Samuel Louie | Sacramento, CA | Pulmonary Disease | $918,361.02 |
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $908,057.73 |
| Mohammadbagher Ziari | Corona, CA | Hematology & Oncology | $904,667.48 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $904,284.24 |
| Noam Drazin | Beverly Hills, CA | Medical Oncology | $845,378.26 |
| Derek Byers | Saint Louis, MO | Pulmonary Disease | $834,800.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.